University of Maryland
Baltimore, Maryland, 21201, United States
NCT Number: NCT01770470
The purpose of the pilot study is to determine the impact of short-term administration of chitosan-containing chewing gum on phosphate levels in patients with elevated serum phosphate levels.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Observational
Baltimore, Maryland, 21201, United States
The impact of using salivary phosphate binders in ESRD patients is not fully known. The purpose of the pilot study is to determine the impact of short-term administration of chitosan-containing chewing gum on phosphate levels in patients with elevated serum phosphate levels.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The product chitosan is contained in a chewing gum formulation
Time frame: 6 weeks
Serum phosphate will be drawn 3 times per week over 2 weeks (during gum therapy), then once at 4 weeks and once at 6 weeks.
Time frame: 6 weeks
Salivary phosphate will be assessed 3 times per week over 2 weeks (during gum therapy), then once at 4 weeks and once at 6 weeks.
University of Maryland, Baltimore
Other
A Pilot Study of Dietary Chitosan Chewing Gum in Dialysis Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03719339
Acute Cellular Graft Rejection, Antibody-mediated Rejection
La Jolla, California, United States
View Trial DetailsNCT03534284
Chronic Disease, Disease Attributes
Seattle, Washington, United States
View Trial DetailsNCT03329521
Chronic Disease, Disease Attributes
London, Ontario, Canada
View Trial DetailsNCT04125537
Chronic Disease, Chronic Kidney Disease Requiring Chronic Dialysis
Arvada, Colorado, United States
View Trial Details